Positive Early Results For Addex Parkinson’s Drug Dipraglurant Spur Hopes For Deal
This article was originally published in The Pink Sheet Daily
In a small, short Phase IIa study, an oral inhibitor of mGluR5 proved effective at reducing dyskinesia caused by levodopa. If future trials are positive, the drug would have a significant positive impact on Parkinson’s patients, says the Michael J. Fox Foundation.
You may also be interested in...
Prexton Therapeutics will be headquartered at the Eclosion incubator facility in Geneva and will advance mGluR compounds for Parkinson’s from the Merck Serono portfolio.
The last five years have seen an explosion in novel approaches to Parkinson’s disease.
Addex Wins Michael J. Fox Foundation Funding To Take Its Dopamine Side Effect Therapy Into Phase II Testing
After a costly 2009 setback, venture philanthropy steps in to help Addex move a risky program forward.